VIR Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
-188000
-100.1%
238.9M
+824051.7%
-29000
-100.0%
64.1M
+26595.8%
240.0K
Cost of Revenue
0
0
0
-100.0%
26.0K
+336.4%
-11000
Gross Profit
-188000
-100.1%
238.9M
+824051.7%
-29000
-100.0%
64.0M
+25415.5%
251.0K
Operating Expenses
104.5M
-36.9%
165.5M
+25.1%
132.3M
+18.1%
112.0M
-35.5%
173.7M
R&D
80.0M
-40.8%
135.3M
+24.2%
108.9M
+23.3%
88.3M
-41.7%
151.5M
SG&A
24.4M
-19.1%
30.2M
+29.4%
23.3M
-1.2%
23.6M
+6.2%
22.2M
Operating Income
-104658000
-242.5%
73.5M
+155.5%
-132290000
-176.1%
-47921000
+72.4%
-173443000
EBITDA
-101888000
-233.6%
76.3M
+158.9%
-129479000
-187.6%
-45023000
+73.6%
-170445000
Net Income
-96252000
-220.2%
80.1M
+163.7%
-125695000
-192.8%
-42923000
+73.7%
-163141000
EPS (Basic)
$-0.57
-218.7%
$0.48
+156.5%
$-0.85
-174.2%
$-0.31
+73.5%
$-1.17
EPS (Diluted)
$-0.57
-221.3%
$0.47
+155.3%
$-0.85
-174.2%
$-0.31
+73.5%
$-1.17
Shares (Diluted)
169.3M
+0.2%
168.9M
+14.6%
147.4M
+5.8%
139.2M
+0.2%
138.9M
Vir Biotechnology (VIR) — Financials